InvestorsHub Logo
Followers 74
Posts 15841
Boards Moderated 0
Alias Born 04/26/2010

Re: ralphey post# 114141

Friday, 09/15/2017 2:03:06 PM

Friday, September 15, 2017 2:03:06 PM

Post# of 425923

since most new RX's are for trigs 200- 500 in hopes of reducing CAD



And you know this how, exactly? Many people here who sought a V scrip did not do it because of elevated TGs, myself included. If 1st A win allowing AMRN/Kowa reps to talk about ANCHOR results were driving NRx higher, we would have seen a noticeable change in the slope of NRx/TRx - but it didn't happen.



The real tragedy here is failure in study design. AMRN should have had included statin intolerant group.



This study design started back in the late 2000's, and including a non-statin group (for whatever reason) would have been a huge risk for AMRN, if they could even have found a couple thousand patients with established CVD or at high risk for developing it who weren't already taking statins - I seriously doubt they could have, because their doctors would have not been giving them the then current standard of care, risking malpractice.

Do you realize the majority of the medical establishment (still) refuses to believe that statin intolerance actually exists as a real medical condition? (it's not the statins making your muscles hurt, it's the exercise routine I put you on to reduce CVD risk)

The Thought Police: To censor and protect. Craig Bruce

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News